about
Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives.Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosisSpleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosisPolymorphisms in the osteopontin promoter affect its transcriptional activity.Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease.Impact of erythropoietin on the effects of irradiation under hypoxia.JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study.No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.Altered fibronectin expression and deposition by myeloproliferative neoplasm-derived mesenchymal stromal cells.The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells.Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis.Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.Angiotensin-converting enzyme (ACE) haplotypes and cyclosporine A (CsA) response: a model of the complex relationship between ACE quantitative trait locus and pathological phenotypesFunctional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasmsArachidonic acid-evoked Ca2+ signals promote nitric oxide release and proliferation in human endothelial colony forming cellsConjugated polymers optically regulate the fate of endothelial colony-forming cellsKinetic and Angiogenic Activity of Circulating Endothelial Colony Forming Cells in Patients with Infantile Haemangioma Receiving PropranololConstitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severityReduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis
P50
Q33368205-4E887842-35D6-4179-BAC6-B7A028ABBE2AQ33431469-F0585CC2-D763-4EEE-AF8D-CC7B3CE4DC02Q34247430-317D34CA-8F31-4249-926E-379A3A7A2550Q34468004-076106D1-B2DA-4CD2-A353-D357E932D1B0Q34652224-4A9906A7-E42C-46B5-A7C6-55C330CCED31Q35548472-8806BE89-844F-428F-A727-79CD1F3B053CQ36047069-06D619A1-14D7-4512-B6FA-1788127C1C5BQ36862456-70BD4146-93F8-4A7E-9F6E-6315437313AFQ38335491-BF77BEF9-516D-4857-A260-FA9BCF4C9AC8Q38722134-C74D2AFF-84BC-481E-87C2-0ABE7F1E6DE1Q39842379-84E89116-F93B-4006-B5FE-612CA795AED1Q40854467-8B2F415B-13CC-4DE8-9096-F6DD0C75C739Q42639974-8846C6B0-4508-407B-98B5-33A71BA602F4Q43065879-AEE300FA-7CFF-48A1-8644-20846A94446EQ43544832-FED619D6-85D1-4470-A7BD-BC87F2BE4CD0Q48187895-3F47404F-6B3A-47D5-9980-315BFEFD7DAFQ52854029-99B85DC9-C89E-4193-B46B-376AC82923CBQ53938164-3F65C8A0-45B5-46E6-983D-2D8F7A1B209BQ58620517-DF762D5F-D2D4-4F8C-88EF-B812516EC069Q61786209-392EBB60-A9C0-4D17-A1D5-27E1B746A6B8Q88343738-B7F8F25D-77F2-44D3-924E-EE60C4C7E092Q90621287-6CB8A5F6-99FA-4BAA-AE84-0039D613BAF7Q90884639-EEC11E6C-EB66-4540-8DAF-1A66C276379FQ92340076-D658C25A-FF37-481D-A776-D8F7DB128B17Q96343908-B0DE7913-0173-4722-B039-0C352B65EC0F
P50
description
researcher, ORCID id # 0000-0002-1862-8168
@en
wetenschapper
@nl
name
Paolo Catarsi
@ast
Paolo Catarsi
@en
Paolo Catarsi
@es
Paolo Catarsi
@nl
type
label
Paolo Catarsi
@ast
Paolo Catarsi
@en
Paolo Catarsi
@es
Paolo Catarsi
@nl
prefLabel
Paolo Catarsi
@ast
Paolo Catarsi
@en
Paolo Catarsi
@es
Paolo Catarsi
@nl
P106
P1153
6506992151
P31
P496
0000-0002-1862-8168